NERV — Minerva Neurosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1598646 ·
Last close
$4.81
Market Cap
$229.67M
52W High
$5.84
52W Low
$3.84
ADV30
220,785
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -10,642,159 | 17,466,285 | 95,088,945 | 24,652,086 | 308,389,568 |
| Mar 2026 | 0 | — | -16,671,552 | -125,404,384 | 94,027,156 | 32,659,770 | 348,041,016 |
| Dec 2025 | 0 | — | -4,981,589 | -283,667,663 | 97,968,888 | 82,301,813 | 238,716,970 |
| Sep 2025 | 0 | — | -2,844,348 | -2,743,954 | 28,092,052 | 12,286,646 | 62,672,322 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,866,040
Investing CF
$-45,294,104
Financing CF
$75,575,032
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-29.16
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-814,204,124
Inventory
—
Receivables
—
ST Investments
$45,405,126
EBIT TTM
$-306,341,757
Pretax Income TTM
$-415,074,589
Interest Exp TTM
$0
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,102,970 | -293,423,177 | 97,968,888 | 238,716,970 | — | -13,510,936 |
| Dec 2024 | 0 | -21,848,386 | 1,438,865 | 37,143,744 | 62,836,844 | — | -19,550,567 |
| Dec 2023 | 0 | -23,119,576 | -30,005,353 | 56,899,750 | 85,357,240 | — | -14,784,732 |
| Dec 2022 | 0 | -25,231,326 | -32,108,676 | 55,087,233 | 75,111,452 | — | -24,645,143 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.42
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $4.81 · call volume: 0 · put volume: 200Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RNA | Atrium Therapeutics, Inc. | $232.98M | $13.62 | — |
| IMUX | IMMUNIC, INC. | $224.59M | $16.46 | — |
| PEPG | PepGen Inc. | $220.94M | $3.19 | — |
| NBP | NovaBridge Biosciences | $218.58M | $1.89 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $218.12M | $4.33 | — |
News headlines (Yahoo Finance, 1h cache)
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
2026-06-01 20:05 · Yahoo
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
2026-05-20 16:00 · Yahoo
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-05-20 13:35 · Yahoo
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
2026-05-05 12:00 · Yahoo
Minerva Announces Leadership Transition
2026-04-02 20:05 · Yahoo
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
2026-03-31 20:05 · Yahoo
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences
2026-04-13 09:08 · Yahoo
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
2026-08-07 11:00 · Yahoo
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-18 20:05 · Yahoo
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
2026-03-25 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.